Product Overview
Bevacizumab | T9904 | TargetMol Chemicals
CAS: 216974-75-3
Smiles:
Formula: N/A
Pathway: Angiogenesis|||Tyrosine Kinase/Adaptors
Target: VEGFR
Receptor: N/A
Bioactivity: Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
Molecular Weight: 149000